Value of community-derived risk models for stratifying patients with non-ST elevation acute coronary syndromes

European Heart Journal

Volumn 26, Issue 9, 2005, Pages 851-852

  Wong, Cheuk Kit ^a   White, Harvey D ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE HEART INFARCTION; ALGORITHM; CARDIOVASCULAR RISK; COMMUNITY; EDITORIAL; HEART MUSCLE ISCHEMIA; HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; ST SEGMENT ELEVATION;

CORONARY DISEASE; HUMANS; MIDDLE AGED; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROGNOSIS; RISK ASSESSMENT; THROMBOLYTIC THERAPY;

EID: 18744372435     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi214     Document Type: Editorial

References (11)

1. de Araújo Gonçalves P, Ferreira J, Aguiar C et al. TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. Eur Heart J 2005;26:865-872. First published on March 11, 2005, doi:10.1093/eurheartj/ehi187.
2. Antman EM, Cohen M, Bernink PJLM et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000;284:835-842.
3. Boersma E, Pieper KS, Steyerberg EW et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: results from an international trial of 9461 patients. Circulation 2000;101:2557-2567.
4. Eagle KA, Lim MJ, Dabbous OH et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 2004;291:2727-2733.
5. Yan AT, Jong P, Yan RT et al. Clinical trial-derived risk model may not generalize to real-world patients with acute coronary syndrome. Am Heart J 2004;148:1020-1027.
6. Ohman EM, Granger CB, Harrington RA et al. Risk stratification and therapeutic decision making in acute coronary syndromes [commentary]. JAMA 2000;284:876-878.
7. The GRACE Investigators. Rationale and design of the GRACE (Global Registry of Acute Coronary Events) project: a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J 2001;141:190-199.
8. Bhatt DL, Roe MT, Peterson ED et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE quality improvement initiative. JAMA 2004;292:2096-2104.
9. Cannon CP, Weintraub WS, Demopoulos LA et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-1887.
10. Morrow DA, Antman EM, Snapinn SM et al. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes: application of the TIMI risk score for UA/NSTEMI in PRISM-Plus. Eur Heart J 2002;23:223-229.
11. Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 2004;110:3206-3212.